Familial Platelet Disorder With Associated Myeloid MalignancyPhase 1NCT07844694
Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder
A Phase 1 study testing Biospecimen Collection, Bone Marrow Aspiration and Bone Marrow Biopsy in people with Familial Platelet Disorder With Associated Myeloid Malignancy, run by OHSU Knight Cancer Institute at 1 site in United States.
Trial summary
This phase I trial studies the safety and side effects of low-dose sirolimus in treating patients with RUNX1 familial platelet disorder (FPD). RUNX1-FPD is a rare inherited disorder with symptoms such as mild to moderately low platelet count, abnormal platelet function, and an increased risk of developing cancers like… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Familial Platelet Disorder With Associated Myeloid Malignancy
- What is being tested?
- Biospecimen Collection, Bone Marrow Aspiration and Bone Marrow Biopsy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Oct 2026to 31 Dec 2030
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient has provided signed, informed consent before initiation of any study specific procedures
- Aged ≥ 18 years at the time of signing the informed consent
- Confirmed pathogenic/likely pathogenic (P/LP) germline RUNX1 variant per ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) RUNX1-specific variant curation rules
- Patient must be willing to provide a bone marrow sample at time of screening and at the end of treatment with sirolimus
- Platelet count of ≥ 50,000/µL
- Creatinine clearance (CrCl) of ≥ 60 mL/min; estimated using the Cockcroft Gault formula or measured by 24 hour urine collection. Exceptions will be allowed, at the discretion of the investigator, for cases of a concomitant medication that alters renal function
Show all 9Show fewer
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 × upper limit of normal (ULN)
- Total bilirubin < 1.5 × ULN
- Left ventricular ejection fraction (EF) > 50% or at the discretion of the investigator
Who cannot join
- Known allergy to sirolimus
- History of major bleeding events that are clinically relevant in the judgement of the investigator or non-major bleeding events that cannot be controlled using SOC practices
- Any known history of lymphoma, myelodysplastic syndrome (MDS), or other hematologic malignancy using International Working Group criteria
- Prior treatment with sirolimus or a rapalog, mTOR inhibitor, or B-cell-depleting therapy within 28 days before study day 1
- Treatment with strong inhibitors of cytochrome P450 3A4 (CYP3A4; e.g., ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, and clarithromycin), strong inducers of CYP3A4 (e.g., rifampin and rifabutin), other drugs that could increase sirolimus blood concentrations (e.g., bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, letermovir, protease inhibitors [e.g., ritonavir, indinavir, boceprevir, and telaprevir], metoclopramide, nicardipine, troleandomycin, and verapamil), other drugs that could decrease sirolimus blood concentrations (e.g., carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort [Hypericum perforatum]), or drugs with blood concentrations that could increase (e.g., verapamil) within 7 days before study day 1, or at the discretion of the investigator
- Use of cannabidiols that increase blood levels of sirolimus, within 7 days before study day 1 or at the discretion of the investigator
Show all 19Show fewer
- Myocardial infarction within 6 months before study day 1, congestive heart failure (New York Heart Association > class II)
- Total cholesterol > 300 mg/dL or triglyceride > 400 mg/dL
- Arterial thrombosis (e.g., stroke or transient ischemic attack) within 6 months before study day 1
- Infection requiring intravenous anti-infective treatment within 1 week of study day 1
- Live vaccines (e.g., measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin [BCG], yellow fever, varicella, and TY21a typhoid) within 28 days before study day 1
- Known diagnosis of tuberculosis is exclusionary to provide protection against reactivation of infections by the immunosuppressive activity of the study drug sirolimus
- The enrollment of a patient with a history of infection with hepatitis B virus (HBV) but with undetectable HBV deoxyribonucleic acid (DNA) by standard institutional testing can be considered after consultation with the investigator
- Patients with history of chronic hepatitis C virus (HCV) must have documentation of completed curative standard of care (SOC) antiviral therapy
- Patients with history of HIV infection must be well-managed with SOC antiretroviral therapy (highly active antiretroviral therapy [HAART])
- Patients with history of Epstein-Barr may be considered after consultation with the treating physician
- Participants who are pregnant may become pregnant, or who are breastfeeding
- Because adequate and well-controlled studies of the impact of sirolimus on fetuses currently do not exist, study approved contraception must be used from start of study therapy to 12 weeks after the last dose of sirolimus
- Adequate and well-controlled studies of infants fed breastmilk from patients undergoing sirolimus therapy do not exist and breastfeeding during study treatment is prohibited
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
OHSU Knight Cancer Institute
Portland, Oregon, 97239
Knight Cancer Institute Clinical Trials Information, 503-494-1080, trials@ohsu.edu
Curtis A. Lachowiez
About this study
Official title: Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder - Part II
This phase I trial studies the safety and side effects of low-dose sirolimus in treating patients with RUNX1 familial platelet disorder (FPD). RUNX1-FPD is a rare inherited disorder with symptoms such as mild to moderately low platelet count, abnormal platelet function, and an increased risk of developing cancers like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It is caused by changes (variants) in the RUNX1 gene that is passed down (inherited) from an affected parent. Sirolimus is typically given to help prevent organ rejection in patients receiving kidney transplants. However, sirolimus may also be able to prevent RUNX1-FPD from progressing to cancers like MDS and AML by targeting another protein called mTORC1. Sirolimus may be a safe treatment for patients with RUNX1-FPD.
Read the detailed description
PRIMARY OBJECTIVE:
- Evaluate the safety and tolerability of low-dose sirolimus in patients with RUNX1 familial platelet disorder (RUNX1-FPD).
SECONDARY OBJECTIVES:
- Evaluate platelet counts. II. Evaluate changes in somatic mutation variant allele frequency (VAF). III. Evaluate somatic mutation acquisition (i.e., mutation burden). IV. Evaluate the change in platelet function. V. Evaluate the change from baseline in bleeding score (International Society on Thrombosis and Haemostasis Bleeding Assessment Tool [ISTH-BAT]).
VI. Evaluate the change in mTORC1 downstream signaling.
EXPLORATORY OBJECTIVES:
- Evaluate the rescue of elevated cytokine profiles. II. Evaluate the reversal of myeloid skewing using colony formation assay. III. Evaluate monocytes using clinical flow cytometry. IV. Evaluate changes in patient-reported quality of life (QoL) outcomes measures (e.g., Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events [PRO-CTCAE]).
- Determine the pharmacokinetics of sirolimus in participants with RUNX1-FPD. VI. Evaluate the correlation between sirolimus trough levels and each endpoint. VII. Make bone marrow smears and bone marrow biopsy slides. VIII. Evaluate the cellularity of bone marrow after study treatment.
OUTLINE:
Patients receive sirolimus orally (PO) once daily (QD) on days 1-168 in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and bone marrow biopsy and/or aspiration throughout the study.
After completion of study treatment, patients are followed for 6 months.
- Being tested
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Questionnaire Administration, Sirolimus
- Medical subject headings
- Platelet Disorder, Familial, with Associated Myeloid Malignancy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biospecimen CollectionProcedure or surgery
Also called Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Undergo collection of blood
Bone Marrow AspirationProcedure or surgery
Undergo bone marrow biopsy/aspiration
Bone Marrow BiopsyProcedure or surgery
Also called Biopsy of Bone Marrow, Biopsy, Bone Marrow
Undergo bone marrow biopsy/aspiration
Questionnaire AdministrationOther
Ancillary studies
SirolimusDrug
Also called AY 22989, AY-22989, AY22989, RAPA
Given PO
| Study group | Role | What they receive |
|---|---|---|
| Treatment (sirolimus) | Experimental | Patients receive sirolimus PO QD on days 1-168 in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and bone marrow biopsy and/or aspiration throughout the study. Receives: Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Other: Questionnaire Administration; Drug: Sirolimus |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of grade 3+ treatment-related adverse events (TRAEs)
The incidence of grade 3+ TRAEs and the total proportion of participants who experienced grade 3+ TRAEs will be estimated and presented with the corresponding 95% exact Clopper Pearson confidence intervals.
Measured: From study day 1 (week 1) to 30 days after the last dose of sirolimus
Secondary outcomes (7)
Change in platelet count
Descriptive statistics on continuous data will include means, medians, standard deviations and ranges, while categorical data will be summarized using frequency counts and percentages. Confidence intervals may be included, as appropriate. Graphical summaries of the data may also be presented.
Measured: From screening, pre dose on study day 1 (week 1) to end of treatment (EOT) (week 24, day 168)
Change in variant allele frequency for existing clones
Descriptive statistics on continuous data will include means, medians, standard deviations and ranges, while categorical data will be summarized using frequency counts and percentages. Confidence intervals may be included, as appropriate. Graphical summaries of the data may also be presented.
Measured: From screening to end of study (EOS) (week 52, day 365)
Change in number of clonal hematopoiesis of indeterminate potential mutations
Descriptive statistics on continuous data will include means, medians, standard deviations and ranges, while categorical data will be summarized using frequency counts and percentages. Confidence intervals may be included, as appropriate. Graphical summaries of the data may also be presented.
Measured: From screening to EOS (week 52, day 365)
Change in percent positivity based on activated GPIIb IIIa and surface P selectin and CD42b
Descriptive statistics on continuous data will include means, medians, standard deviations and ranges, while categorical data will be summarized using frequency counts and percentages. Confidence intervals may be included, as appropriate. Graphical summaries of the data may also be presented.
Measured: From screening, pre dose on study day 1 (week 1) to EOT (week 24, day 168)
Change in aggregation from baseline based on thromboelastography (TEG)
Descriptive statistics on continuous data will include means, medians, standard deviations and ranges, while categorical data will be summarized using frequency counts and percentages. Confidence intervals may be included, as appropriate. Graphical summaries of the data may also be presented.
Measured: From screening, pre dose on study day 1 (week 1) to EOT (week 24, day 168)
Change in the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool score
Descriptive statistics on continuous data will include means, medians, standard deviations and ranges, while categorical data will be summarized using frequency counts and percentages. Confidence intervals may be included, as appropriate. Graphical summaries of the data may also be presented.
Measured: From study day 1 (week 1) to EOS (week 52, day 365)
Change in the relative amount of the protein 4eBP1
Will be based on flow cytometry and immunohistochemistry assays. Descriptive statistics on continuous data will include means, medians, standard deviations and ranges, while categorical data will be summarized using frequency counts and percentages. Confidence intervals may be included, as appropriate. Graphical summaries of the data may also be presented.
Measured: From screening, pre dose on study day 1 (week 1) to EOS (week 52, day 365)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2026
- Study start5 Oct 2026
- Primary completion30 Jun 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Familial Platelet Disorder With Associated Myeloid MalignancyStudies of the same condition, open and under way.
- More trials run by OHSU Knight Cancer InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 6 participants (estimated)
Sponsor and investigators
- Lead sponsor
- OHSU Knight Cancer Institute
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), Oregon Health and Science University, M.D. Anderson Cancer Center
- Responsible party
- Principal investigator, Curtis Lachowiez, OHSU Knight Cancer Institute
- Investigators
- Curtis A Lachowiez, Principal investigator, OHSU Knight Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07844694
- Sponsor's protocol ID
- STUDY00028610
- Other IDs
- NCI-2026-03902, STUDY00028610, P30CA069533
- Status last verified
- Oct 2026
- First submitted
- 21 Sep 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder - Part II
- ClinicalTrials.gov ID
- NCT07844694
- Acronym / sponsor ID
- STUDY00028610
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 6 participants (estimated)
- Lead sponsor
- OHSU Knight Cancer InstituteUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), Oregon Health and Science University, M.D. Anderson Cancer Center
- Study start
- 5 Oct 2026 (actual)
- Primary completion
- 30 Jun 2030 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 28 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase I trial studies the safety and side effects of low-dose sirolimus in treating patients with RUNX1 familial platelet disorder (FPD). RUNX1-FPD is a rare inherited disorder with symptoms such as mild to moderately low platelet count, abnormal platelet function, and an increased risk of developing cancers like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It is caused by changes (variants) in the RUNX1 gene that is passed down (inherited) from an affected parent. Sirolimus is typically given to help prevent organ rejection in patients receiving kidney transplants. However, sirolimus may also be able to prevent RUNX1-FPD from progressing to cancers like MDS and AML by targeting another protein called mTORC1. Sirolimus may be a safe treatment for patients with RUNX1-FPD.
Detailed description
PRIMARY OBJECTIVE:
- Evaluate the safety and tolerability of low-dose sirolimus in patients with RUNX1 familial platelet disorder (RUNX1-FPD).
SECONDARY OBJECTIVES:
- Evaluate platelet counts. II. Evaluate changes in somatic mutation variant allele frequency (VAF). III. Evaluate somatic mutation acquisition (i.e., mutation burden). IV. Evaluate the change in platelet function. V. Evaluate the change from baseline in bleeding score (International Society on Thrombosis and Haemostasis Bleeding Assessment Tool [ISTH-BAT]).
VI. Evaluate the change in mTORC1 downstream signaling.
EXPLORATORY OBJECTIVES:
- Evaluate the rescue of elevated cytokine profiles. II. Evaluate the reversal of myeloid skewing using colony formation assay. III. Evaluate monocytes using clinical flow cytometry. IV. Evaluate changes in patient-reported quality of life (QoL) outcomes measures (e.g., Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events [PRO-CTCAE]).
- Determine the pharmacokinetics of sirolimus in participants with RUNX1-FPD. VI. Evaluate the correlation between sirolimus trough levels and each endpoint. VII. Make bone marrow smears and bone marrow biopsy slides. VIII. Evaluate the cellularity of bone marrow after study treatment.
OUTLINE:
Patients receive sirolimus orally (PO) once daily (QD) on days 1-168 in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and bone marrow biopsy and/or aspiration throughout the study.
After completion of study treatment, patients are followed for 6 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment (sirolimus) | Experimental | Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspiration, Procedure: Bone Marrow Biopsy, Other: Questionnaire Administration, Drug: SirolimusPatients receive sirolimus PO QD on days 1-168 in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and bone marrow biopsy and/or aspiration throughout the study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Patient has provided signed, informed consent before initiation of any study specific procedures
- Aged ≥ 18 years at the time of signing the informed consent
- Confirmed pathogenic/likely pathogenic (P/LP) germline RUNX1 variant per ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) RUNX1-specific variant curation rules
- Patient must be willing to provide a bone marrow sample at time of screening and at the end of treatment with sirolimus
- Platelet count of ≥ 50,000/µL
Key exclusion criteria (19 listed)
- Known allergy to sirolimus
- History of major bleeding events that are clinically relevant in the judgement of the investigator or non-major bleeding events that cannot be controlled using SOC practices
- Any known history of lymphoma, myelodysplastic syndrome (MDS), or other hematologic malignancy using International Working Group criteria
- Prior treatment with sirolimus or a rapalog, mTOR inhibitor, or B-cell-depleting therapy within 28 days before study day 1
- Treatment with strong inhibitors of cytochrome P450 3A4 (CYP3A4; e.g., ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, and clarithromycin), strong inducers of CYP3A4 (e.g., rifampin and rifabutin), other drugs that could increase sirolimus blood concentrations (e.g., bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, letermovir, protease inhibitors [e.g., ritonavir, indinavir, boceprevir, and telaprevir], metoclopramide, nicardipine, troleandomycin, and verapamil), other drugs that could decrease sirolimus blood concentrations (e.g., carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort [Hypericum perforatum]), or drugs with blood concentrations that could increase (e.g., verapamil) within 7 days before study day 1, or at the discretion of the investigator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biospecimen CollectionAlso: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen CollectionUndergo collection of blood | Procedure or surgery | Treatment (sirolimus) |
| Bone Marrow AspirationUndergo bone marrow biopsy/aspiration | Procedure or surgery | Treatment (sirolimus) |
| Bone Marrow BiopsyAlso: Biopsy of Bone Marrow, Biopsy, Bone MarrowUndergo bone marrow biopsy/aspiration | Procedure or surgery | Treatment (sirolimus) |
| Questionnaire AdministrationAncillary studies | Other | Treatment (sirolimus) |
| SirolimusAlso: AY 22989, AY-22989, AY22989, RAPAGiven PO | Drug | Treatment (sirolimus) |
Primary outcome
Incidence of grade 3+ treatment-related adverse events (TRAEs)
Time frame: From study day 1 (week 1) to 30 days after the last dose of sirolimus
The incidence of grade 3+ TRAEs and the total proportion of participants who experienced grade 3+ TRAEs will be estimated and presented with the corresponding 95% exact Clopper Pearson confidence intervals.
7 secondary outcomes
Change in platelet count
Time frame: From screening, pre dose on study day 1 (week 1) to end of treatment (EOT) (week 24, day 168)
Change in variant allele frequency for existing clones
Time frame: From screening to end of study (EOS) (week 52, day 365)
Change in number of clonal hematopoiesis of indeterminate potential mutations
Time frame: From screening to EOS (week 52, day 365)
Change in percent positivity based on activated GPIIb IIIa and surface P selectin and CD42b
Time frame: From screening, pre dose on study day 1 (week 1) to EOT (week 24, day 168)
Change in aggregation from baseline based on thromboelastography (TEG)
Time frame: From screening, pre dose on study day 1 (week 1) to EOT (week 24, day 168)
Change in the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool score
Time frame: From study day 1 (week 1) to EOS (week 52, day 365)
Change in the relative amount of the protein 4eBP1
Time frame: From screening, pre dose on study day 1 (week 1) to EOS (week 52, day 365)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
Related trials for Familial Platelet Disorder With Associated Myeloid Malignancy
RecruitingObservational study
Longitudinal Studies of Patient With FPDMM
Inherited Hematological Diseases, Rare Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Curtis A Lachowiez principal investigator
OHSU Knight Cancer Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Biospecimen Collection, Bone Marrow Aspiration and Bone Marrow Biopsy in people with Familial Platelet Disorder With Associated Myeloid Malignancy, run by OHSU Knight Cancer Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Knight Cancer Institute Clinical Trials Information (503-494-1080, trials@ohsu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of grade 3+ treatment-related adverse events (TRAEs) (time frame: From study day 1 (week 1) to 30 days after the last dose of sirolimus). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.